# Myeloma Investment Fund

> Myeloma Investment Fund is a VC fund in Brookline backing Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Brookline, United States
- Total investments: 12
- Last investment: May 2025
- Lead investor: 33%
- Last updated: Aug 2026
- Website: https://myelomainvestmentfund.org/

Myeloma Investment Fund is a new, independent, self-sustaining venture fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 75% |
| Medical | 4 | 33% |
| Health Care | 4 | 33% |
| Biopharma | 3 | 25% |
| Therapeutics | 3 | 25% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Venture - Series Unknown | 3 | 25% |
| Seed | 2 | 17% |
| Series B | 1 | 8% |
| Series C | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 67% |
| Canada | 1 | 8% |
| Israel | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stylus Medicine | Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders. The company is based in Cambridge, Massachusetts. | $85M | Series A | May 12, 2025 |  |
| Reverb Therapeutics | Reverb Therapeutics engages in the development of treatments for cancer and other diseases. | $12M | Seed | Feb 19, 2025 |  |
| Umoja Biopharma | Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $100M | Series C | Jan 14, 2025 |  |
| Indapta Therapeutics | Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers. | $22.5M | Venture - Series Unknown | Dec 17, 2024 |  |
| Trio Pharmaceuticals | Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California. | $3.1M | Seed | Dec 03, 2024 |  |
| Nammi Therapeutics | Nammi Therapeutics is an immunotherapy company that develops nano-enabled chemo-immunotherapy for the treatment of cancer. | $1M | Series B | Aug 06, 2024 |  |
| Dynamic Cell Therapies | Dynamic Cell Therapies develops controllable CAR T cells for the treatment of cancers. | $1M | Venture - Series Unknown | Jul 11, 2024 |  |
| Reverb Therapeutics | Reverb Therapeutics engages in the development of treatments for cancer and other diseases. |  | Seed | Nov 15, 2023 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $12.5M | Venture - Series Unknown | Nov 17, 2022 |  |
| Triumvira Immunologics | Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cellreceptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer. | $45M | Series A | Mar 17, 2022 |  |

10 of 12 investments shown.

## Co-investors
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 4 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 3 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [B Capital](https://shizune.co/investors/profile/b-capital-group) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- ATEM Capital Fund LP — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Myeloma Investment Fund invest in?

Myeloma Investment Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Myeloma Investment Fund last invest?

The most recent investment recorded for Myeloma Investment Fund closed in May 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co